Clinical Trial: A Study of JNJ-86974680 in Participants With Advanced Non-small Cell Lung Cancer
Study Status: Completed
Recruit Status: RECRUITING
Condition: Carcinoma, Non-small-Cell Lung
Study Type: INTERVENTIONAL
Official Title: A Phase 1 Study of JNJ-86974680, an A2a Receptor Antagonist, Administered as Monotherapy and in Combination With Cetrelimab and Radiotherapy for Advanced Non-small Cell Lung Cancer
Brief Summary:
The purpose of this study is to determine a safe and tolerable dose(s) of JNJ-86974680 for further research in combination with cetrelimab and radiation therapy.
Read more